second cancer trang 2 tải miễn phí từ TAILIEUCHUNG

"second cancer" trang 2 - tải miễn phí từ Tailieuchung

DocOx (AIO-PK0106): A phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinoma

DocOx (AIO-PK0106): A phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinoma

9 54 1

The effect of patient characteristics on second primary cancer risk in France

The effect of patient characteristics on second primary cancer risk in France

14 41 1

Types of second primary cancer influence overall survival in cutaneous melanoma

Types of second primary cancer influence overall survival in cutaneous melanoma

8 26 1

Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: A retrospective cohort study

Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: A retrospective cohort study

9 41 1

Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer

Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer

9 41 1

Risks and cancer associations of metachronous and synchronous multiple primary cancers: A 25-year retrospective study

Risks and cancer associations of metachronous and synchronous multiple primary cancers: A 25-year retrospective study

10 48 1

A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO)

A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO)

9 59 1

A multi-center phase II study and biomarker analysis of combined cetuximab and modified FOLFIRI as second-line treatment in patients with metastatic gastric cancer

A multi-center phase II study and biomarker analysis of combined cetuximab and modified FOLFIRI as second-line treatment in patients with metastatic gastric cancer

10 43 1

Network meta-analysis of eribulin versus other chemotherapies used as second- or later-line treatment in locally advanced or metastatic breast cancer

Network meta-analysis of eribulin versus other chemotherapies used as second- or later-line treatment in locally advanced or metastatic breast cancer

15 21 1

Phase II trial of eribulin mesylate as a firstor second-line treatment for locally advanced or metastatic breast cancer: A multicenter, single-arm trial

Phase II trial of eribulin mesylate as a firstor second-line treatment for locally advanced or metastatic breast cancer: A multicenter, single-arm trial

7 41 1

Osimertinib in advanced EGFRT790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group

Osimertinib in advanced EGFRT790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group

12 24 1

Family history of breast cancer as a second primary malignancy in relatives: A nationwide cohort study

Family history of breast cancer as a second primary malignancy in relatives: A nationwide cohort study

8 51 1

Using second harmonic generation to predict patient outcome in solid tumors

Using second harmonic generation to predict patient outcome in solid tumors

10 31 1

Efficacy of second-line treatment and prognostic factors in patients with advanced malignant peritoneal mesothelioma: A retrospective study

Efficacy of second-line treatment and prognostic factors in patients with advanced malignant peritoneal mesothelioma: A retrospective study

9 15 1

Real-world effectiveness of second-line Afatinib versus chemotherapy for the treatment of advanced lung squamous cell carcinoma in immunotherapy-naïve patients

Real-world effectiveness of second-line Afatinib versus chemotherapy for the treatment of advanced lung squamous cell carcinoma in immunotherapy-naïve patients

9 42 1

Does second-look endoscopy reduce the bleeding after gastric endoscopic submucosal dissection for patients receiving antithrombotic therapy?

Does second-look endoscopy reduce the bleeding after gastric endoscopic submucosal dissection for patients receiving antithrombotic therapy?

10 24 1

Clonal relationship of synchronous head and neck cancer and esophageal cancer assessed by single nucleotide polymorphism-based loss of heterozygosity analysis

Clonal relationship of synchronous head and neck cancer and esophageal cancer assessed by single nucleotide polymorphism-based loss of heterozygosity analysis

9 81 0

Relative efficacy of interventions in the treatment of second-line non-small cell lung cancer: A systematic review and network meta-analysis

Relative efficacy of interventions in the treatment of second-line non-small cell lung cancer: A systematic review and network meta-analysis

16 76 0

The relationship between peripheral neuropathy and efficacy in second-line chemotherapy for unresectable advanced gastric cancer: A prospective observational multicenter study protocol (IVY)

The relationship between peripheral neuropathy and efficacy in second-line chemotherapy for unresectable advanced gastric cancer: A prospective observational multicenter study protocol (IVY)

6 71 0

Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer

Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer

9 17 1

Đã phát hiện trình chặn quảng cáo AdBlock

Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.